Gyre Therapeutics, Inc. (GYRE) is a San Diego-based, commercial-stage biopharmaceutical company whose operations are split between the United States and China. Through its majority-owned Gyre Pharmaceuticals unit it sells ETUARY (pirfenidone), the first approved idiopathic pulmonary fibrosis therapy in China, along with Etorel and Contiva, while its pipeline centers on F351 (hydronidone) for liver fibrosis and, following the May 2026 Cullgen acquisition, a set of targeted protein degrader candidates.
The stock traded at $4.48 in Thursday’s session, up 3.23% and $0.14 from the previous completed session’s close of $4.34. The direction is unambiguously higher, though the shares opened at $4.47, reached roughly $4.70 in early trade, and then gave back most of that advance. No verified news catalyst was identified for the gain; the move is best characterized as a technical rebound in a volatile small-cap tape.
No verified news or fundamental catalyst found in company releases, securities filings, clinical updates, or analyst actions accounts for Thursday’s gain. The most recent material disclosure remains the third-quarter report published on November 5, which showed revenue of $32.9 million against roughly $28.4 million expected, earnings of $0.04 per share versus a consensus loss, and reaffirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million. That report is two weeks old and cannot explain today’s price action.
The likelier explanation is mechanical. Gyre shares fell 4.82% on Wednesday and had dropped roughly 40% over the prior three months, leaving the stock within striking distance of its 52-week low near $3.97. Moves of this magnitude are routine for this name: across the last 69 completed sessions, the average absolute daily change was about 3.4%, and 26 of those sessions produced a swing equal to or larger than today’s 3.23%. Order flow is thin — individual five-minute bars on Thursday regularly printed volumes of a few hundred shares — so modest buying interest can move the quote several percentage points. A rebound after a sharp single-session decline, amplified by low liquidity, is the most consistent read on the tape.
Volume by midday was roughly 94,000 shares, already close to the stock’s average full-day turnover of about 107,000 shares over the past 30 sessions — elevated relative to the time of day, but not the kind of surge that typically accompanies a fundamental re-rating. The intraday high of about $4.70 failed to hold, and the stock settled back toward the $4.45–$4.50 area, a pattern more consistent with short-term trading than durable accumulation.
The broader backdrop offered little help. The SPDR S&P Biotech ETF (XBI) was up about 0.3% and the iShares Biotechnology ETF (IBB) was roughly flat, so sector sentiment was neutral-to-slightly positive. Small caps were weaker, with the iShares Russell 2000 ETF (IWM) down about 1.3%, and the Invesco QQQ Trust (QQQ) lower by roughly 0.7%. Gyre therefore outperformed both its sector and the broad tape, which reinforces the stock-specific, flow-driven interpretation. No major moving average was reclaimed; the shares remain well below their 50- and 200-day trend lines and far under the 52-week high above $9.
The score runs from 0 to 100, where 0 means no meaningful news and a price move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, rare move. Gyre earns 5 out of 100.
The verified news component is close to nil: nothing was released on Thursday, and the last material event — a solid third-quarter beat — was published two weeks ago and is modest relative to a company with roughly $450 million in market value and $100 million-plus in annual revenue. The price component is equally unremarkable. Today’s 3.23% gain was slightly smaller than the stock’s typical daily move of about 3.4%, and comparable or larger swings occurred 26 times in the last 69 sessions. A weak news backdrop plus an ordinary move for this name produces a deliberately low score.
Attention remains fixed on China’s National Medical Products Administration, which accepted the hydronidone new drug application for chronic hepatitis B-associated liver fibrosis in May 2026 under a priority review pathway. A decision is expected around year-end 2026 or early in the first quarter of 2027, with a commercial launch in China targeted for the first half of 2027 if approval is granted. That single regulatory event carries more valuation weight than any quarterly result.
On the pipeline side, the company has guided to initiating a Phase 2 trial of CG001419 in the first half of 2027, Phase 1 dose-escalation data for CG009301 in the second half of 2027, and an IND filing for CG923308 in the first quarter of 2027. Investors will also track U.S. requirements for F351 in MASH-associated fibrosis, which remain under discussion with the FDA, along with the cost of absorbing Cullgen, which drove a wider nine-month operating loss of $34.9 million. Financing needs, procurement pressure on Contiva and Etorel in China, and the pace of ETUARY volume growth are the key swing factors, and with a small float and limited analyst coverage, headline risk in either direction is likely to be amplified.
Tickeron’s Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, risk profile, performance metrics, and the specific symbols they trade, so the featured group rotates as market conditions change. Reviewing the trending list can help traders see which approaches are working right now and how they might complement their own process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 32 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Indicator exited the oversold zone, 35 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where GYRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on GYRE as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on November 17, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.596). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology